| Literature DB >> 34379667 |
Winson Fu Zun Yang1,2, Rachael Zhi Yi Lee1, Sangita Kuparasundram3, Terina Tan4, Yiong Huak Chan1, Konstadina Griva5, Rathi Mahendran1,4.
Abstract
STUDYEntities:
Mesh:
Year: 2021 PMID: 34379667 PMCID: PMC8357113 DOI: 10.1371/journal.pone.0255901
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Participants demographics from different treatment phases.
| N (%) | <6 months | 6–9 months | >9 months | Completed |
|---|---|---|---|---|
| (n = 77) | (n = 42) | (n = 34) | (n = 84) | |
|
| ||||
| Female | 47 (61.00%) | 21 (50.00%) | 20 (58.80%) | 55 (65.50%) |
| Male | 30 (39.00%) | 21 (50.00%) | 14 (41.20%) | 29 (34.50%) |
|
| ||||
| 21–30 | 17 (22.10%) | 3 (7.10%) | 2 (5.90%) | 15 (17.90%) |
| 31–40 | 21 (27.30%) | 12 (28.60%) | 4 (11.80%) | 13 (15.50%) |
| 41–50 | 19 (24.70%) | 13 (31.00%) | 8 (23.50%) | 19 (22.60%) |
| 51–60 | 14 (18.20%) | 8 (19.00%) | 7 (20.60%) | 22 (26.20%) |
| 61–70 | 4 (5.20%) | 6 (14.30%) | 11 (32.40%) | 13 (15.50%) |
| 71–80 | 2 (2.60%) | 0 (0.00%) | 2 (5.90%) | 2 (2.40%) |
|
| ||||
| Not married | 31 (40.30%) | 10 (23.80%) | 7 (20.60%) | 35 (41.70%) |
| Married | 46 (59.70%) | 32 (76.20%) | 27 (79.40%) | 49 (58.30%) |
|
| ||||
| Your spouse | 21 (27.30%) | 14 (33.30%) | 17 (50.00%) | 26 (31.00%) |
| Your child | 4 (5.20%) | 0 (0.00%) | 1 (2.90%) | 5 (6.00%) |
| Your grandparent | 3 (3.90%) | 0 (0.00%) | 1 (2.90%) | 3 (3.60%) |
| Your parent | 41 (53.20%) | 23 (54.80%) | 12 (35.30%) | 42 (50.00%) |
| Sibling | 8 (10.40%) | 5 (11.90%) | 3 (8.80%) | 8 (9.50%) |
|
| ||||
| Brain tumor | 2 (2.60%) | 0 (0.00%) | 0 (0.00%) | 2 (2.40%) |
| Breast | 12 (15.60%) | 13 (31.00%) | 9 (26.50%) | 20 (23.80%) |
| Gastro-intestinal/Colorectal/Stomach | 16 (20.80%) | 5 (11.90%) | 2 (5.90%) | 20 (23.80%) |
| Gynaecological | 2 (2.60%) | 2 (4.80%) | 3 (8.80%) | 2 (2.40%) |
| Haemotological/Leukemia/Lymphoma/Myeloma | 6 (7.80%) | 4 (9.50%) | 7 (20.60%) | 7 (8.30%) |
| Lung | 15 (19.50%) | 8 (19.00%) | 9 (26.50%) | 18 (21.40%) |
| Multisite | 1 (1.30%) | 3 (7.10%) | 0 (0.00%) | 3 (3.60%) |
| NPC/Throat/Oral | 1 (1.30%) | 2 (4.80%) | 1 (2.90%) | 5 (6.00%) |
| Others | 15 (19.50%) | 2 (4.80%) | 2 (5.90%) | 3 (3.60%) |
| Pancreas | 6 (7.80%) | 0 (0.00%) | 0 (0.00%) | 3 (3.60%) |
| Renal | 1 (1.30%) | 3 (7.10%) | 1 (2.90%) | 1 (1.20%) |
|
| ||||
| Early (stages 0–2) | 10 (13.00%) | 5 (11.90%) | 6 (17.60%) | 28 (32.30%) |
| Late (stages 3–4) | 67 (87.00%) | 37 (88.10%) | 28 (82.40%) | 56 (66.70%) |
|
| ||||
| Total | 10.95 (10.57) | 7.40 (9.06) | 10.09 (8.49) | 10.80 (8.93) |
| Depression | 3.52 (4.08) | 2.10 (3.20) | 2.88 (2.78) | 3.01 (3.22) |
| Anxiety | 2.83 (3.48) | 1.57 (3.05) | 2.85 (3.12) | 3.06 (3.26) |
| Stress | 4.60 (3.87) | 3.74 (3.58) | 4.35 (3.31) | 4.73 (3.66) |
|
| ||||
| Personal roles | 1.88 (1.89) | 1.16 (1.71) | 1.62 (2.02) | 1.71 (2.08) |
| Role management | 2.11 (2.51) | 1.95 (1.74) | 1.87 (2.52) | 1.79 (2.62) |
Unstandardized regression coefficients of predictors of depressive symptoms.
| Unstandardized b (SE) | DASS | DASS | DASS | DASS |
|---|---|---|---|---|
| Total | Depression | Anxiety | Stress | |
|
| R2 = 0.033 | R2 = 0.031 | R2 = 0.047 | R2 = 0.024 |
| Intercept | 10.92 (1.88) | 3.55 (0.69) | 2.77 (0.65) | 4.60 (0.73) |
| Age group (21–30 as reference) | ||||
| 31–40 | -1.86 (2.07) | -0.97 (0.76) | 0.06 (0.71) | -0.95 (0.8) |
| 41–50 | -3.07 (1.98) | -1.42 (0.73) | -0.54 (0.68) | -1.11 (0.77) |
| 51–60 | 1.49 (2.04) | -0.11 (0.75) | 1.45 (0.70) | 0.16 (0.79) |
| 61–70 | -2.20 (2.22) | -1.40 (0.82) | 0.04 (0.77) | -0.85 (0.86) |
| 71–80 | -1.45 (4.15) | -1.27 (1.52) | 0.64 (1.43) | -0.81 (1.61) |
| Cancer Stage (early as reference) | ||||
| Late (stages 3–4) | 0.54 (1.52) | 0.33 (0.56) | -0.37 (0.52) | 0.57 (0.59) |
|
| R2 = 0.22 | R2 = 0.22 | R2 = 0.18 | R2 = 0.20 |
| Personal care | 0.75 (1.70) | 0.26 (0.62) | 0.53 (0.60) | -0.04 (0.66) |
| Role management | 2.80 (1.58) | 1.32 (0.58) | 0.42 (0.56) | 1.06 (0.62) |
| treatment phase (<6 months as reference) | ||||
| 6–9 months (intermediate) | -1.75 (1.75) | -0.73 (0.64) | -0.83 (0.62) | -0.18 (0.68) |
| >9 months (chronic) | -1.08 (1.88) | -0.54 (0.69) | -0.19 (0.67) | -0.35 (0.73) |
| completed | -0.48 (1.44) | -0.55 (0.53) | 0.00 (0.51) | 0.06 (0.56) |
| Personal care x treatment phase (DA x<6 months as reference) | ||||
| Personal care x 6–9 months | 4.93 (2.37) | 1.66 (0.87) | 1.01 (0.84) | 2.26 (0.93) |
| Personal care x >9 months | 5.91 (2.75) | 1.42 (1.01) | 1.97 (0.98) | 2.53 (1.07) |
| Personal care x completed | 2.06 (2.04) | 1.00 (0.75) | -0.16 (0.73) | 1.22 (0.80) |
| Role management x treatment phase (DA x<6 months as reference) | ||||
| Role management x 6–9 months | -2.74 (2.55) | -1.29 (0.93) | -0.18 (0.91) | -1.26 (1.00) |
| Role management x >9 months | -4.49 (2.68) | -1.51 (0.98) | -1.07 (0.96) | -1.91 (1.05) |
| Role management x completed | -2.89 (1.96) | -1.59 (0.72) | -0.55 (0.70) | -0.75 (0.76) |
DASS: Depression Anxiety Stress Scale; DA: Daily activity
* p<0.05,
** p<0.01,
*** p<0.001
Fig 1Relationship between unmet role management needs and DASS depression score across treatment phases.
Greater unmet role management needs were associated with greater Depression, Anxiety, and Stress Scale (DASS) depression score in general. Moreover, compared with their loved ones undergoing treatment for less than six months, family caregivers with care recipient who have completed treatment had less positive relationship between unmet role management needs and DASS depression score.